Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer
Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retr...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/24/5770 |
| _version_ | 1797381709112541184 |
|---|---|
| author | Lukas Scheipner Hanna Zurl Julia V. Altziebler Georg P. Pichler Stephanie Schöpfer-Schwab Samra Jasarevic Michael Gaisl Klara C. Pohl Karl Pemberger Stefan Andlar Georg C. Hutterer Uros Bele Conrad Leitsmann Marianne Leitsmann Herbert Augustin Richard Zigeuner Sascha Ahyai Johannes Mischinger |
| author_facet | Lukas Scheipner Hanna Zurl Julia V. Altziebler Georg P. Pichler Stephanie Schöpfer-Schwab Samra Jasarevic Michael Gaisl Klara C. Pohl Karl Pemberger Stefan Andlar Georg C. Hutterer Uros Bele Conrad Leitsmann Marianne Leitsmann Herbert Augustin Richard Zigeuner Sascha Ahyai Johannes Mischinger |
| author_sort | Lukas Scheipner |
| collection | DOAJ |
| description | Purpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (<i>p</i> = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, <i>p</i> = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, <i>p</i> = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols. |
| first_indexed | 2024-03-08T20:55:20Z |
| format | Article |
| id | doaj.art-1166a50c779348caab749caa41d0caf6 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T20:55:20Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1166a50c779348caab749caa41d0caf62023-12-22T13:58:49ZengMDPI AGCancers2072-66942023-12-011524577010.3390/cancers15245770Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder CancerLukas Scheipner0Hanna Zurl1Julia V. Altziebler2Georg P. Pichler3Stephanie Schöpfer-Schwab4Samra Jasarevic5Michael Gaisl6Klara C. Pohl7Karl Pemberger8Stefan Andlar9Georg C. Hutterer10Uros Bele11Conrad Leitsmann12Marianne Leitsmann13Herbert Augustin14Richard Zigeuner15Sascha Ahyai16Johannes Mischinger17Department of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaDepartment of Urology, Medical University of Graz, 8010 Graz, AustriaPurpose: To test the association between the Charlson–Deyo Comorbidity Index (CCI) and the recurrence of non-muscle-invasive bladder cancer (NMIBC). Methods: NMIBC (Ta, T1, TIS) patients who underwent transurethral resection of bladder tumor (TURB) between 2010 and 2018 were identified within a retrospective data repository of a large university hospital. Kaplan–Meier estimates and uni- and multivariable Cox regression models tested for differences in risk of recurrence according to low vs. high comorbidity burden (CCI ≤ 4 vs. >4) and continuously coded CCI. Results: A total of 1072 NMIBC patients were identified. The median follow-up time of the study population was 55 months (IQR 29.6–79.0). Of all 1072 NMIBC patients, 423 (39%) harbored a low comorbidity burden vs. 649 (61%) with a high comorbidity burden. Overall, the rate of recurrence was 10% at the 12-month follow-up vs. 22% at the 72-month follow-up. In low vs. high comorbidity burden groups, rates of recurrence were 6 vs. 12% at 12 months and 18 vs. 25% at 72 months of follow-up (<i>p</i> = 0.02). After multivariable adjustment, a high comorbidity burden (CCI > 4) independently predicted a higher risk of recurrence (HR 1.42, 95% confidence interval (CI) 1.06–1.92, <i>p</i> = 0.018). After multivariable adjustment, the hazard of recurrence increased by 5% per each one-unit increase on the CCI scale (HR 1.05, 95% CI 1.00–1.10, <i>p</i> = 0.04). Conclusions: Comorbidities in NMIBC patients are common. Our data suggest that patients with higher CCI have an increased risk of BC recurrence. As a consequence, patients with a high comorbidity burden should be particularly encouraged to adhere to NMIBC guidelines and conform to follow-up protocols.https://www.mdpi.com/2072-6694/15/24/5770CCINMIBCrecurrenceCharlson comorbidity indexpredictor |
| spellingShingle | Lukas Scheipner Hanna Zurl Julia V. Altziebler Georg P. Pichler Stephanie Schöpfer-Schwab Samra Jasarevic Michael Gaisl Klara C. Pohl Karl Pemberger Stefan Andlar Georg C. Hutterer Uros Bele Conrad Leitsmann Marianne Leitsmann Herbert Augustin Richard Zigeuner Sascha Ahyai Johannes Mischinger Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer Cancers CCI NMIBC recurrence Charlson comorbidity index predictor |
| title | Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer |
| title_full | Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer |
| title_fullStr | Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer |
| title_full_unstemmed | Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer |
| title_short | Charlson–Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer |
| title_sort | charlson deyo comorbidity index as a novel predictor for recurrence in non muscle invasive bladder cancer |
| topic | CCI NMIBC recurrence Charlson comorbidity index predictor |
| url | https://www.mdpi.com/2072-6694/15/24/5770 |
| work_keys_str_mv | AT lukasscheipner charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT hannazurl charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT juliavaltziebler charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT georgppichler charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT stephanieschopferschwab charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT samrajasarevic charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT michaelgaisl charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT klaracpohl charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT karlpemberger charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT stefanandlar charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT georgchutterer charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT urosbele charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT conradleitsmann charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT marianneleitsmann charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT herbertaugustin charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT richardzigeuner charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT saschaahyai charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer AT johannesmischinger charlsondeyocomorbidityindexasanovelpredictorforrecurrenceinnonmuscleinvasivebladdercancer |